Free Newsletter
Endo chief meets healthcare reform head-on
Free newsletter via e-mail
Tools
Anticipating the effects of U.S. healthcare reform, Endo Pharmaceuticals Chief Executive David Holveck says his company is diversifying beyond pain medications into other maladies--and beyond drugs, into diagnostics, devices and health services. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: